Are injectables an option if I can’t use hormones?
If you can’t or prefer not to use hormones, selected injectables (such as platelet-rich plasma or polynucleotides) may be considered as adjuncts for genitourinary syndrome of menopause (GSM) after optimising non-hormonal foundations. They don’t replace moisturisers or suitable lubricants and their evidence is still emerging, so expectations should be cautious and progress reviewed. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Are injectables an option if I can’t use hormones? Sometimes, yes—as add-ons after the non-hormonal basics are in place. Genitourinary syndrome of menopause (GSM)—also called vaginal atrophy/GSM—arises from low oestrogen, so the vaginal epithelium thins, pH rises and protective Lactobacillus falls. That biology increases friction, burning and micro-tears, especially at the vestibule (entrance). First, build a robust non-hormonal routine: a scheduled vaginal moisturiser (many prefer hyaluronic-acid gels) 2–4 times weekly for baseline hydration, plus a compatible personal lubricant for higher-friction moments—water-based (versatile, condom-friendly), silicone-based (long-glide for a tender entrance) or oil-based (rich feel but may degrade latex condoms/toys). Keep external care gentle (lukewarm water; bland emollient as a soap substitute); switch to breathable underwear and avoid fragranced washes or liners.
Where injectables fit in this pathway. If foundations reduce day-to-day sting but you still get “”paper-cut”” splits or insertional pain, your clinician may discuss platelet-rich plasma (PRP) or polynucleotides as adjuncts. PRP is prepared from your own blood and injected in tiny amounts to nudge local repair and blood flow. Polynucleotides (highly purified DNA fragments, sometimes salmon-derived) are biostimulatory and water-binding, placed superficially to condition tissue and improve slip. Neither corrects the low-oestrogen biology the way local vaginal oestrogen or vaginal DHEA can; instead, they target mechanics—helping the sore entrance tolerate movement and intimacy with fewer micro-tears. Responses vary; many plans involve 2–3 sessions spaced 4–8 weeks apart with review points, not open-ended courses.
Targeting matters more than the label. If your pain is entrance-focused, ensure any treatment—moisturiser, lubricant or procedure—reaches the vestibule. Internal-only approaches often miss the hotspot. For injectables, precise, superficial placement at symptomatic sites (vestibule/posterior fourchette) is key. Continue generous lubricant for higher-friction activities; silicone-based options often provide the longest glide when the entrance is delicate. If protective pelvic floor guarding developed after painful experiences, pelvic health physiotherapy and, where helpful, graded dilators can be transformative; injections alone cannot relax muscles.
Safety, limits and practicalities. Short-lived tenderness, pinpoint bruising and spotting are common after injectables; transient flare in sensitivity can occur. Defer if you have active thrush/BV/UTI, malodorous discharge, unexplained bleeding, fever, or recent pelvic/perineal surgery without clearance. People with bleeding disorders or on anticoagulants need personalised planning (PRP relies on platelets). For polynucleotides, severe fish allergy is a typical exclusion (check product source; ® belongs to its owner). Set clear goals (fewer micro-tears; easier initial penetration; less sting with urine contact), use symptom diaries, and review at 6–12 weeks to decide on maintenance or alternatives.
How this looks in real life. Many who cannot use hormone therapy find that disciplined foundations + precise vestibule-targeted care already reduce flares. When injectables help, people often describe calmer walking/cycling and “”less scratchy”” penetration over weeks; improvements are gradual and not permanent, so you’ll reassess at 3–6 and 6–12 months. If progress stalls after two sessions, pause and re-check the diagnosis (e.g., lichen sclerosus, contact dermatitis, vestibulodynia), product placement (is the entrance being treated?), and co-triggers (tight sports kit, saddle pressure, fragranced products). For clarity on the process, see how treatment steps are sequenced and a transparent overview of treatment prices for budgeting and follow-up planning.
Clinical Context
Who might consider injectables without hormones? People with GSM whose main barrier is vestibular stinging or micro-tears despite a solid routine of moisturiser and a compatible lubricant—and who cannot/choose not to use local hormones. They may also suit those partially improved on non-hormonal care but still limited by friction at the entrance.
Who should avoid or delay? Anyone with red flags: fever, severe pelvic pain, malodorous green/grey discharge, visible haematuria, or new post-menopausal bleeding. Defer during active BV/thrush/UTI or while healing from recent pelvic/perineal surgery. Severe fish allergy typically excludes salmon-derived polynucleotides; significant bleeding risk needs individual planning. If deep pelvic pain dominates, investigate other drivers (e.g., endometriosis/adenomyosis) rather than escalating surface treatments.
Next steps. Keep washing gentle (lukewarm water; bland emollient as a soap substitute), wear breathable underwear, change out of sweaty kit promptly, and avoid fragranced products. Choose a lubricant that truly suits your needs (silicone-based often gives the longest glide). Consider psychosexual support if apprehension is sustaining pain. Set review points at 6–12 weeks and again at 3–6 months to adjust towards the lowest effective maintenance once comfortable.
Evidence-Based Approaches
Guideline first lines (UK): UK guidance prioritises vaginal moisturisers and lubricants and, when symptoms affect quality of life, low-dose local vaginal oestrogen. For plain-English self-care and red flags, see NHS: vaginal dryness. For clinical recommendations, see the NICE Menopause Guideline (NG23).
Product detail & cautions: UK information for local therapies (oestrogens, prasterone/DHEA) is listed in the British National Formulary (BNF). Even if hormones are unsuitable, BNF entries help frame alternatives and contraindications for related treatments.
Comparators with stronger evidence: Systematic reviews in the Cochrane Library show local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, tablets/pessaries and rings—these are the benchmarks non-hormonal adjuncts are compared against.
Emerging evidence for injectables: Peer-reviewed pilot studies and overviews indexed on PubMed report potential benefit of PRP and polynucleotides for GSM-related discomfort, but highlight heterogeneity in preparation, dosing and follow-up. Accordingly, they remain adjuncts, chosen after shared decision-making about benefits, limits, costs and maintenance.
Applying the evidence: If hormones are not an option, build foundations meticulously, address pelvic floor contributors, and consider injectables only when entrance-focused friction persists. Plan short series with clear goals and scheduled reviews; prioritise accurate vestibule targeting over brand names. ® belongs to its owner.